Subscribe To
RDY / COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
RDY News
By Zacks Investment Research
November 2, 2023
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Pre more_horizontal
By Zacks Investment Research
October 30, 2023
Dr. Reddy's (RDY) Q2 Earnings and Revenues Beat Estimates
Dr. Reddy's (RDY) reports better-than-expected fiscal second-quarter 2024 results where both earnings and revenues beat estimates, driven by growth in more_horizontal
By Zacks Investment Research
October 26, 2023
All You Need to Know About Doctor Reddy's (RDY) Rating Upgrade to Strong Buy
Doctor Reddy's (RDY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong more_horizontal
By Zacks Investment Research
October 4, 2023
3 Reasons Growth Investors Will Love Doctor Reddy's (RDY)
Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. more_horizontal
By Zacks Investment Research
September 26, 2023
Doctor Reddy's (RDY) Loses -6.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Doctor Reddy's (RDY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement am more_horizontal
By Zacks Investment Research
September 18, 2023
Here is Why Growth Investors Should Buy Doctor Reddy's (RDY) Now
Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. more_horizontal
By Zacks Investment Research
August 31, 2023
Looking for a Growth Stock? 3 Reasons Why Doctor Reddy's (RDY) is a Solid Choice
Doctor Reddy's (RDY) could produce exceptional returns because of its solid growth attributes. more_horizontal
By Zacks Investment Research
August 18, 2023
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looki more_horizontal